

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of SinoMab BioScience Limited (the “**Company**”) dated 4 February 2021 (the “**Announcement**”). Unless otherwise stated, the capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to provide Shareholders and potential investors of the Company with further information that, to the best knowledge, information and belief of the Directors having made all reasonable enquiry, Dragon Capital Special Opportunities SPC is ultimately 100% owned by Mr. Zhai Jun (翟雋) and the ultimate 100% beneficial owner of Dragon Capital Special Opportunities SPC segregated portfolio named Dragon Capital Special Opportunities 2 SP is Ms. Liu Yan (劉妍).

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 5 February 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.